Kathryn M. Boxmeyer Net Worth

What's Kathryn Boxmeyer's mailing address?

Kathryn's mailing address filed with the SEC is C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON, MA, 02111.

Insiders trading at Paratek Pharmaceuticals

Over the last 10 years, insiders at Paratek Pharmaceuticals have traded over $9,410,794 worth of Paratek Pharmaceuticals stock and bought 1,743,576 units worth $13,751,429 . The most active insiders traders include James D Dondero, Bioventures Cayman Ltd Hbm et Evan Loh. On average, Paratek Pharmaceuticals executives and independent directors trade stock every 24 days with the average trade being worth of $63,310. The most recent stock trade was executed by Randall B. Brenner on 8 August 2023, trading 27,603 units of PRTK stock currently worth $60,727.

What does Paratek Pharmaceuticals do?

paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.

Paratek Pharmaceuticals executives and stock owners

Paratek Pharmaceuticals executives and other stock owners filed with the SEC include:

• Dr. Evan Loh FACC, FAHA, M.D.,
  CEO & Director
• Dr. Evan Loh,
  CEO & Director
• Michael F. Bigham CPA, CPA, M.B.A., MBA,
  Exec. Chairman
• Michael F. Bigham CPA, M.B.A., CPA, MBA,
  Exec. Chairman
• Adam Woodrow,
  Pres & Chief Commercial Officer
• Leonid Sevastyanov,
  Independent Director
• Sergey Guz,
  Independent Director
• Aleksandr Sukhoruchenko,
  Director
• Vadim Gorbunov,
  Director
• Yuliya Yakunina,
  Director, Director of Economics
• Timofey Prokopov,
  Vice President for Finance and Investment
• Anna Kinash,
  Chief Accountant
• Vadim Muzyaev,
  President, Deputy Chairman of the Board
• Vadim Yakunin,
  Chairman of the Board, Adviser to President
• Randall B. Brenner,
  Chief Devel. & Regulatory Officer
• Karen McGrath,
  Sr. VP of HR
• Christine R. Coyne M.B.A.,
  VP of Marketing
• Ben Strain,
  VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
• Jason Burdette,
  Sr. VP of Technical Operations
• Sarah Higgins,
  VP, Controller and Interim Principal Financial & Accounting Officer
• William M. Haskel,
  Sr. VP, Chief Legal Officer, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Michael Bigham,
  Exec. Chairman of the Board
• Fund Iii, L.P.Omega Fund Iv...,
  
• Douglas W. Pagan,
  Chief Financial Officer
• Thomas John Dietz,
  Director
• Robert S Radie,
  Director
• Richard J. Lim,
  Director
• Timothy R Franson,
  Director
• Jeffrey Stein,
  Director
• Kristine Peterson,
  Director
• William M. Haskel,
  CLO, General Counsel & Sec.
• Evan Loh,
  CEO
• Randall B. Brenner,
  Chief Development & Regulatory
• Kathryn M. Boxmeyer,
  See Remarks
• Bioventures Cayman Ltd Hbm,
  10% owner
• Rolf K Hoffmann,
  Director
• Minnie Baylor Henry,
  Director
• James D Dondero,
  10% owner